Newsroom

COLLIERVILLE, Tenn.--(BUSINESS WIRE)--Mueller Industries, Inc. (NYSE: MLI) today reported fourth quarter and full year results for 2025. For the Fourth Quarter 2025 versus Fourth Quarter 2024: Net sales: $962.4 million vs. $923.5 million, up 4.2%. Operating income: $172.0 million vs. $170.3 million, up 1.0%. Net income: $153.7 million vs. $137.7 million, up 11.6%. Diluted EPS: $1.38 vs. $1.21, up 14.0%. For the Full Year 2025 versus the Full Year 2024: Net sales: $4.2 billion vs. $3.8 billion,...

MADISON, Wis.--(BUSINESS WIRE)--The NMPA has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic medical device in China....

SAN FRANCISCO--(BUSINESS WIRE)--RapidFort raises $42M to scale a new approach to automated software supply chain security, and combat increasing vulnerability exploitation....

TORONTO--(BUSINESS WIRE)--Silver Storm Mining Ltd. (“Silver Storm” or the "Company") (TSX.V: SVRS | OTCQX: SVRSF | FSE: SVR), is pleased to report that all eight new flotation cells have been fabricated and delivered to site at the Company’s 100% owned La Parrilla Silver Mine Complex (the “La Parrilla Complex”) in Durango, Mexico. The installation of the new 1,000 ft3 flotation cells, when combined with the existing processing equipment, will allow the processing capacity of the sulphide flotat...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced leadership transitions for its next phase of innovation. Travis Thompson, who began at Bicycle in April 2018 and most recently served as Bicycle’s senior vice president and chief accounting officer and previously spent his career at EY in its life...

BUFORD, Ga.--(BUSINESS WIRE)--OneWater Marine Inc. (NASDAQ: ONEW) (“OneWater” or the “Company”) today announced that it has completed the sale of Ocean Bio-Chem Holdings, Inc. (“Ocean Bio-Chem” or “OBCI”) as part of its broader portfolio optimization strategy focused on core assets and long-term value creation. Proceeds from the transaction will be used to reduce debt and further strengthen the balance sheet. “As part of our long-term strategy, we are focused on simplifying the business and all...

SAN FRANCISCO & DOHA, Qatar--(BUSINESS WIRE)--At Web Summit Qatar, Visa (NYSE:V) and UnionPay International (UPI) announced an agreement to enable cross-border money movement into Chinese Mainland through Visa Direct. Once fully rolled out, clients will be able to send cross-border remittances and business-to-consumer payouts to more than 95 percent of UnionPay International debit cardholders in Chinese Mainland, through a single connection. By connecting Visa Direct’s global money movement net...

PLANTATION, Fla.--(BUSINESS WIRE)--NationsBenefits®, the leader in healthcare fintech and integrated benefit solutions, today announced a retail technology integration with Giant Eagle, one of the nation’s largest food retailers and distributors. Through NationsBenefits real-time Basket Adjudication Service (BAS) and the NationsBenefits Benefits Mastercard® Flex Card, eligible health-plan members can pay for fresh produce, pantry staples, and over-the-counter wellness items at more than 200 Gia...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones Internet UCITS ETF 02.02.2026 FDNU IE00BG0SSC32 2,300,002.00 USD 83,246,689.78 36.194  ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would of...